IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo.
about
Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumorsClinical manufacturing of CAR T cells: foundation of a promising therapyRegulation of IL-10 and IL-12 production and function in macrophages and dendritic cellsMesothelin-Targeted CARs: Driving T Cells to Solid TumorsImproving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationSmart CARs engineered for cancer immunotherapyEmerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cellsCAR-modified T-cell therapy for cancer: an updated review.A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients.Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicineChimeric antigen receptor-redirected T cells return to the benchA new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy.Chimeric antigen receptor T cells: a novel therapy for solid tumors.Adoptive T-Cell Therapy for Solid Tumors.The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy.Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps.Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.Intraperitoneal immunotherapy: historical perspectives and modern therapy.The Unique Molecular and Cellular Microenvironment of Ovarian CancerCurrent approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment.Development of CAR T cells designed to improve antitumor efficacy and safety.Harnessing the immune response to target tumors.Commentary: IL-12-secreting tumor-targeted chimeric antigen receptor T cells: An unaddressed concern on Koneru et al. (2015).Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen.IL12-mediated sensitizing of T-cell receptor-dependent and -independent tumor cell killingArmored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment.Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities.Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy.Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment.The latest animal models of ovarian cancer for novel drug discovery.Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.IL-36α suppresses proliferation of ovarian cancer cells.T-bet promotes potent antitumor activity of CD4+ CAR T cells.Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System.MUC16 mutations improve patients' prognosis by enhancing the infiltration and antitumor immunity of cytotoxic T lymphocytes in the endometrial cancer microenvironmentRegulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment
P2860
Q26741260-C61D37DA-DD64-40AD-B95A-FD3FBD70FB69Q26747037-0C187005-B67B-4E15-AC8E-FD93C820A46DQ26766184-FCD72070-57EE-4145-AFA0-93F99905FF36Q26778759-E176FFB6-37BA-468F-934E-D9423E80DCAFQ28068378-98FF2D22-79FB-4717-8027-95734FB56871Q28087236-85438F70-F78A-4316-AEA9-4437F84370B7Q33833475-07F29BDF-019B-448A-AB17-24879FB20E0AQ34044213-9D35BD7D-C009-4CD6-8E99-84A357023EF1Q35627284-72BA6A33-7AF8-4422-8433-1B3C37D79208Q36317366-A5EBD7E5-A209-4F68-A935-E7C1D409ECA6Q37224420-DA293E51-C7DE-4A92-A5D5-3583DC0CFA7DQ37301510-257D649D-527D-4401-A9E8-4FB6BD71B110Q37555940-F5E5A902-5490-4324-851D-50215F0BABE2Q37728639-7A65884D-15F1-41DD-B8F9-977BFBE3BA38Q38754498-4DC91EFF-7846-4C1A-BAF7-B8E31D0FDB40Q38775177-98443903-A674-491E-885A-E8392BDBF455Q38779032-75DF4C3B-0FD5-423B-9B7E-8ADD2829E4D9Q38845812-9542C3F1-6235-4042-8157-B98F3E4DBE62Q38890450-595E8403-985E-4DD8-B925-2E5B7AB140C0Q38945853-347F388A-F08E-4955-AF6A-532112CECDE6Q39005211-C29D2C98-D3B9-4D39-9943-2FA3986C7AB4Q39169603-68A7F483-9380-4168-B4D5-CED2C4A2A9EFQ39194733-64AEE322-E28C-442C-BA43-7E5415E97D4CQ39200527-A6B93BC3-AD66-4D2C-8B1B-2FDBC16FFC8EQ39377265-87BC10AB-0C39-4B6A-AB5F-EB96EFAA94CBQ40438508-7E119C44-851F-4A62-A6AA-A8D2996E65D5Q40973052-BFA1E440-DC11-4530-A621-29C2275275E3Q40987686-E6C38D63-280A-4104-AA9B-6ED4F6132638Q41619752-9B545BAA-EF2D-41B0-9AD6-BF90C1835F3FQ45832774-C17A53D4-0C1E-41F4-9E0D-83D909DC8133Q45868285-DD2CDC18-3F1C-4AB0-A2BD-540305E1AA93Q45870945-1D4F7077-B98A-4824-AE4D-46ED7DFA8D89Q47309343-69DE7DFE-0243-4180-A5B7-7DFD1070E67AQ47553013-D692FBDF-7F1C-49FF-A7CB-F31376EDD0DCQ47561397-4F92CBDB-EFD5-4877-9413-D3DDF870CA53Q50941305-6A4CA0EE-FB94-49DE-A2C6-F04036A28CF1Q52668512-2FFAE313-1D0D-4905-9DBB-63B26520082BQ55378779-45DFE8E4-46E9-47F0-9F39-967E3EE0CA81Q57135123-E2741B1F-3A5C-4AEC-8553-14ABACBCAE87Q58773649-51C55461-20CD-4911-B652-435BEDA1AD47
P2860
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
IL-12 secreting tumor-targeted ...... dicate ovarian tumors in vivo.
@ast
IL-12 secreting tumor-targeted ...... dicate ovarian tumors in vivo.
@en
type
label
IL-12 secreting tumor-targeted ...... dicate ovarian tumors in vivo.
@ast
IL-12 secreting tumor-targeted ...... dicate ovarian tumors in vivo.
@en
prefLabel
IL-12 secreting tumor-targeted ...... dicate ovarian tumors in vivo.
@ast
IL-12 secreting tumor-targeted ...... dicate ovarian tumors in vivo.
@en
P2093
P2860
P1433
P1476
IL-12 secreting tumor-targeted ...... adicate ovarian tumors in vivo
@en
P2093
David Spriggs
Mythili Koneru
Renier J Brentjens
Susmith Koneru
P2860
P304
P356
10.4161/2162402X.2014.994446
P577
2015-01-23T00:00:00Z